Developer docs
API playgroundTry for free, no card

Search company profiles

MINAKEM SAS

Full company profile

uuid0002tem

Namestring
MINAKEM SAS
Legal namestring
Minakem SAS
Websiteurl
minakem.com
Company typeenum
Private
Founded yearint
1964
Descriptiontext

Minakem SAS is a France-based Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs), including Highly Potent APIs (HPAPIs), controlled substances, steroids, and complex small molecules. The company operates four cGMP-compliant production sites — two in France (Beuvry-la-Forêt and Dunkerque), one in Belgium (Louvain-la-Neuve), and one in Canada (Montreal) — representing over 500 m³ of total reaction capacity, with exports to 35 countries and a portfolio of more than 100 Drug Master Files across the US, EU, Japan, China, Korea, and Canada. Minakem's core technical capabilities include HPAPI manufacturing at OEB5 containment levels (OEL down to 0.1 µg/m³), industrial preparative HPLC purification, cryogenic reactions to -80°C, advanced chiral and organometallic synthesis, solid-state chemistry, and corticosteroid manufacturing, with a 2024 fully automated facility at Beuvry-la-Forêt representing the latest capital investment.

The company generates revenue through a hybrid CDMO/generic API model: project-based custom development and manufacturing fees from pharmaceutical clients, complemented by recurring commercial supply of a generic API portfolio spanning oncology (vinca alkaloids), cardiovascular, CNS, gastrointestinal, and veterinary therapeutic areas. Long-term supply agreements, DMF-backed qualifications, and the addition of GMP excipients and building blocks as adjacent product lines reinforce an integrated go-to-market approach. Distribution is exclusively direct B2B, with sales driven by industry trade shows (BePharma, DCAT Week, CPhI), regulatory qualification, and technical engagement rather than intermediaries.

Minakem is a wholly-owned subsidiary of Minafin Group, a diversified chemical group, and has grown primarily through acquisition — the Beuvry-la-Forêt site (2005), the former AstraZeneca Dunkirk plant (2009), the Ajinomoto Omnichem Louvain-la-Neuve site (2015), and the Delmar Chemicals Montreal facility (2023). The company holds 501-1,000 employees and is led by Olivier Ubrich, appointed CEO of the Health Chemistry Division of Minafin Group in September 2024. Certifications across cGMP, USFDA, EDQM, Health Canada, AFMPS, ISO 27001, and multiple quality/religious certifications (Halal, Kosher, non-GMO) support multinational pharmaceutical client requirements.

Short descriptiontext

Minakem SAS is a France-based pharmaceutical CDMO manufacturing Active Pharmaceutical Ingredients (APIs), including highly potent compounds, steroids, and controlled substances, for global pharmaceutical and generic drug companies across four cGMP sites in France, Belgium, and Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersDunkerque, France
HQ citystring
Dunkerque
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, active pharmaceutical ingredients, highly potent APIs, API contract manufacturing, generic API supply
Industry4 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAC
High-Potency API (HPAPI) Development & Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Industrial Organic Chemicals2860
Product category
Pharmaceutical Contract Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1API Manufacturing Services
TypeOne Time License
Description

Minakem generates revenue through custom development and manufacturing of Active Pharmaceutical Ingredients (APIs) for pharmaceutical companies. Revenue is earned through project-based development fees, technology transfer services, and long-term commercial supply agreements. The company operates on a CDMO model where clients pay for process development, scale-up, and manufacturing services, typically under multi-year supply contracts with recurring revenue from approved API sources.

minakem.com
2Generic API Supply
TypeSubscription Recurring
Description

Revenue from the commercial supply of generic APIs from the company's portfolio, including steroids, controlled substances, Vinca alkaloids, and other small molecule APIs. Supply agreements typically involve recurring orders as pharmaceutical formulations receive regulatory approval.

minakem.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom API Development and Manufacturing - Quote-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing for custom API development, scale-up, and manufacturing is determined through project-specific quotes based on technical requirements, batch size, regulatory filing needs, and supply volume commitments.

minakem.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Minakem is a B2B Contract Development and Manufacturing Organization (CDMO) that develops and manufactures Active Pharmaceutical Ingredients (APIs), including highly potent APIs (HPAPIs), controlled substances, and steroids, for pharmaceutical companies worldwide. It provides custom process development, analytical method development, scale-up, technology transfer, and commercial supply from four cGMP-compliant production facilities in France, Belgium, and Canada. Its portfolio also includes more than 30 generic APIs, GMP excipients, and chemical building blocks for organic synthesis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successful FDA inspection completed at Montreal facility (November 2025)
+2 more records
Product overview1 text field

MINAKEM SAS is a Contract Development and Manufacturing Organization (CDMO) providing comprehensive pharmaceutical manufacturing services. The company operates as a single unified offering combining API Manufacturing Services, API Development Services, Analytical Sciences, and Specialized Technologies including Highly Potent APIs (HPAPIs) and Solid State Chemistry. Their portfolio includes over 30 generic Active Pharmaceutical Ingredients across therapeutic areas including oncology (Vinblastine, Vincristine, Vindesine, Vinorelbine), cardiovascular, gastrointestinal, and veterinary applications, complemented by Building Blocks for organic synthesis and GMP Excipients. The company operates four manufacturing facilities across France (Beuvry-la-Forêt and Dunkerque), Belgium (Louvain-la-Neuve), and Canada (Montreal), serving customers in 35 countries with cGMP-compliant production from gram to multi-ton scale.

Product and service9 records
1API Manufacturing Services
CategoryContract API Manufacturing
Description

Contract development and manufacturing services for Active Pharmaceutical Ingredients (APIs) including small molecule APIs, HPAPIs, controlled substances, and steroids, spanning from clinical to commercial scale at four cGMP-compliant production sites in France, Belgium, and Canada. Targeted at pharmaceutical companies needing reliable, long-term API supply.

2API Development Services
CategoryContract API Development
Description

Comprehensive API development including process design, scale-up, and analytical development for custom small molecule and HPAPI projects from discovery through commercialization, intended for pharmaceutical companies outsourcing route scouting, process optimization, and technology transfer.

3Analytical Sciences
CategoryAnalytical Services
Description

Analytical method development, validation, and testing services that support API manufacturing and regulatory submissions, available to pharmaceutical customers across all four Minakem production sites.

4Highly Potent APIs (HPAPIs)
CategoryHighly Potent API Manufacturing
Description

Development and manufacturing of highly potent active pharmaceutical ingredients with OEL limits down to 0.1 µg/m³, including cytotoxic and cytostatic compounds, produced under strict OEB5 containment conditions for oncology and other high-potency pharmaceutical applications.

5Solid State Chemistry Services
CategorySpecialized API Technologies
Description

Solid state characterization, polymorph screening, crystallization process development, particle size optimization, and intellectual property support for API development customers.

6Specialized Chemical Reactions
CategorySpecialized API Technologies
Description

Advanced chemical synthesis services including cryogenic reactions (down to -80°C), cyanation, halogenation, hydrogenation, carbonylation, fractional distillation, and preparative chromatography for complex API manufacturing projects.

7Building Blocks
CategoryChemical Building Blocks
Description

Catalog product of chemical intermediates and building blocks for organic synthesis, including cyclobutane derivatives, cyclopropyl compounds, tetrahydropyran derivatives, and other specialized reagents for pharmaceutical synthesis customers.

8GMP Excipients
CategoryPharmaceutical Excipients
Description

Pharmaceutical-grade excipients product line including Sodium Stearyl Fumarate GMP and Propyl gallate GMP, meeting USP and EP standards for pharmaceutical formulation customers.

9Generic APIs Portfolio
CategoryGeneric API Supply
Description

Portfolio of more than 30 generic active pharmaceutical ingredients supplied under cGMP, including APIs for oncology (vinca alkaloids: Vinblastine, Vincristine, Vindesine, Vinorelbine), cardiovascular, central nervous system, gastrointestinal, and veterinary applications, sold directly to generic drug manufacturers.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Delmar Chemicals Inc. (Acquisition by Minafin Group)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

Minafin Group acquired Delmar Chemicals Inc. in Montreal, Canada in July 2023 to expand its Healthcare Chemicals division and establish presence in North America. The acquisition includes a portfolio of generic active pharmaceutical ingredients and enhances R&D and manufacturing capacities, especially in organic synthesis and corticosteroids. This enables Minakem to serve the North American market directly.

minakem.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hovione is a privately held, Portugal-based CDMO specializing in small-molecule APIs and HPAPIs with manufacturing in Europe and the U.S. It is the closest functional comparable to Minakem in terms of HPAPI containment levels, complex chemistry (cryogenic, particle engineering) and CDMO-plus-generics mix.

TypeDirect peer
Description

Siegfried is a Swiss-listed CDMO offering API manufacturing plus finished dosage forms with sites in Switzerland, the U.S., Germany, Spain and Malta. Comparable to Minakem in small-molecule API CDMO model and global multi-site footprint, though larger and more integrated into drug product.

TypeDirect peer
Description

EuroAPI is a French API manufacturer spun out of Sanofi, focused on small-molecule APIs and intermediates across steroids, hormones and complex chemistry. It mirrors Minakem's European footprint, steroid franchise and CDMO activity, and is a directly comparable European API specialist competitor.

TypeDirect peer
Description

Seqens is a France-based specialty chemicals and pharmaceutical CDMO producing APIs, intermediates and complex molecules across multiple sites. It is comparable to Minakem as a French-headquartered, multi-site API CDMO serving global pharma with similar chemistry capabilities.

TypeDirect peer
Description

Cambrex is a U.S.-headquartered CDMO focused exclusively on small-molecule APIs and intermediates with HPAPI capabilities across North America and Europe. Acquired by Permira/Novo Holdings, it competes head-on with Minakem in custom API development, scale-up and commercial supply.

TypeDirect peer
Description

Veranova is a CDMO spun out of Johnson Matthey in 2023 specializing in HPAPIs, complex APIs and antibody-drug conjugate payloads. It is highly comparable to Minakem given shared HPAPI focus, containment capabilities and oncology customer base.

TypeDirect peer
Description

CARBOGEN AMCIS is a Switzerland/India-headquartered CDMO with strong HPAPI capabilities, complex chemistry and a global API manufacturing network. Comparable to Minakem in HPAPI containment, complex synthesis and integrated development-to-commercial services.

TypeBroad incumbent
Description

Lonza operates the world's largest CDMO franchise spanning small-molecule APIs, biologics and cell & gene therapies. Its small-molecules division competes directly with Minakem in API development and HPAPI manufacturing but offers a far broader integrated services portfolio.

TypeBroad incumbent
Description

Catalent (now under Novo Holdings) is a global CDMO offering drug substance (including HPAPI) and drug product services across biologics, softgel and inhalation. It overlaps with Minakem in HPAPI and small-molecule API CDMO but is much larger and more diversified.

TypeEmerging player
Description

Aurobindo and its CDMO arm Apitoria operate large-scale generic API manufacturing globally, including corticosteroids and complex small molecules. Comparable to Minakem's generic API supply business, though with a much larger commercial-scale footprint and broader finished-dose integration.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MINAKEM SAS

Pharmaceutical Contract Manufacturingminakem.com

Minakem SAS is a France-based pharmaceutical CDMO manufacturing Active Pharmaceutical Ingredients (APIs), including highly potent compounds, steroids, and controlled substances, for global pharmaceutical and generic drug companies across four cGMP sites in France, Belgium, and Canada.

What MINAKEM SAS does

Minakem SAS is a France-based Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs), including Highly Potent APIs (HPAPIs), controlled substances, steroids, and complex small molecules. The company operates four cGMP-compliant production sites — two in France (Beuvry-la-Forêt and Dunkerque), one in Belgium (Louvain-la-Neuve), and one in Canada (Montreal) — representing over 500 m³ of total reaction capacity, with exports to 35 countries and a portfolio of more than 100 Drug Master Files across the US, EU, Japan, China, Korea, and Canada. Minakem's core technical capabilities include HPAPI manufacturing at OEB5 containment levels (OEL down to 0.1 µg/m³), industrial preparative HPLC purification, cryogenic reactions to -80°C, advanced chiral and organometallic synthesis, solid-state chemistry, and corticosteroid manufacturing, with a 2024 fully automated facility at Beuvry-la-Forêt representing the latest capital investment.

The company generates revenue through a hybrid CDMO/generic API model: project-based custom development and manufacturing fees from pharmaceutical clients, complemented by recurring commercial supply of a generic API portfolio spanning oncology (vinca alkaloids), cardiovascular, CNS, gastrointestinal, and veterinary therapeutic areas. Long-term supply agreements, DMF-backed qualifications, and the addition of GMP excipients and building blocks as adjacent product lines reinforce an integrated go-to-market approach. Distribution is exclusively direct B2B, with sales driven by industry trade shows (BePharma, DCAT Week, CPhI), regulatory qualification, and technical engagement rather than intermediaries.

Minakem is a wholly-owned subsidiary of Minafin Group, a diversified chemical group, and has grown primarily through acquisition — the Beuvry-la-Forêt site (2005), the former AstraZeneca Dunkirk plant (2009), the Ajinomoto Omnichem Louvain-la-Neuve site (2015), and the Delmar Chemicals Montreal facility (2023). The company holds 501-1,000 employees and is led by Olivier Ubrich, appointed CEO of the Health Chemistry Division of Minafin Group in September 2024. Certifications across cGMP, USFDA, EDQM, Health Canada, AFMPS, ISO 27001, and multiple quality/religious certifications (Halal, Kosher, non-GMO) support multinational pharmaceutical client requirements.

MINAKEM SAS firmographics

Firmographics
Name
MINAKEM SAS
Legal name
Minakem SAS
Website
https://minakem.com
Company type
Private
Founded year
1964
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Minakem SAS is a France-based pharmaceutical CDMO manufacturing Active Pharmaceutical Ingredients (APIs), including highly potent compounds, steroids, and controlled substances, for global pharmaceutical and generic drug companies across four cGMP sites in France, Belgium, and Canada.
Ownership category
akta.pro rank

MINAKEM SAS industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAC
High-Potency API (HPAPI) Development & Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical CDMO services
  • Active pharmaceutical ingredients
  • Highly potent APIs
  • API contract manufacturing
  • Generic API supply

Where MINAKEM SAS is headquartered

Location

Headquarters

HQ city
Dunkerque
HQ country
France
HQ region
Europe

Offices4 records

Markets served

MINAKEM SAS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. API Manufacturing Services: Minakem generates revenue through custom development and manufacturing of Active Pharmaceutical Ingredients (APIs) for pharmaceutical companies. Revenue is earned through project-based development fees, technology transfer services, and long-term commercial supply agreements. The company operates on a CDMO model where clients pay for process development, scale-up, and manufacturing services, typically under multi-year supply contracts with recurring revenue from approved API sources.
  2. Generic API Supply: Revenue from the commercial supply of generic APIs from the company's portfolio, including steroids, controlled substances, Vinca alkaloids, and other small molecule APIs. Supply agreements typically involve recurring orders as pharmaceutical formulations receive regulatory approval.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom API Development and Manufacturing - Quote-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

MINAKEM SAS product offering

Product offering

Core offering

Minakem is a B2B Contract Development and Manufacturing Organization (CDMO) that develops and manufactures Active Pharmaceutical Ingredients (APIs), including highly potent APIs (HPAPIs), controlled substances, and steroids, for pharmaceutical companies worldwide. It provides custom process development, analytical method development, scale-up, technology transfer, and commercial supply from four cGMP-compliant production facilities in France, Belgium, and Canada. Its portfolio also includes more than 30 generic APIs, GMP excipients, and chemical building blocks for organic synthesis.

Product overview

MINAKEM SAS is a Contract Development and Manufacturing Organization (CDMO) providing comprehensive pharmaceutical manufacturing services. The company operates as a single unified offering combining API Manufacturing Services, API Development Services, Analytical Sciences, and Specialized Technologies including Highly Potent APIs (HPAPIs) and Solid State Chemistry. Their portfolio includes over 30 generic Active Pharmaceutical Ingredients across therapeutic areas including oncology (Vinblastine, Vincristine, Vindesine, Vinorelbine), cardiovascular, gastrointestinal, and veterinary applications, complemented by Building Blocks for organic synthesis and GMP Excipients. The company operates four manufacturing facilities across France (Beuvry-la-Forêt and Dunkerque), Belgium (Louvain-la-Neuve), and Canada (Montreal), serving customers in 35 countries with cGMP-compliant production from gram to multi-ton scale.

Differentiator

Problem solved

Functional benefit

Products and services

  • API Manufacturing Services Contract development and manufacturing services for Active Pharmaceutical Ingredients (APIs) including small molecule APIs, HPAPIs, controlled substances, and steroids, spanning from clinical to commercial scale at four cGMP-compliant production sites in France, Belgium, and Canada. Targeted at pharmaceutical companies needing reliable, long-term API supply.
  • API Development Services Comprehensive API development including process design, scale-up, and analytical development for custom small molecule and HPAPI projects from discovery through commercialization, intended for pharmaceutical companies outsourcing route scouting, process optimization, and technology transfer.
  • Analytical Sciences Analytical method development, validation, and testing services that support API manufacturing and regulatory submissions, available to pharmaceutical customers across all four Minakem production sites.
  • Highly Potent APIs (HPAPIs) Development and manufacturing of highly potent active pharmaceutical ingredients with OEL limits down to 0.1 µg/m³, including cytotoxic and cytostatic compounds, produced under strict OEB5 containment conditions for oncology and other high-potency pharmaceutical applications.
  • Solid State Chemistry Services Solid state characterization, polymorph screening, crystallization process development, particle size optimization, and intellectual property support for API development customers.
  • Specialized Chemical Reactions Advanced chemical synthesis services including cryogenic reactions (down to -80°C), cyanation, halogenation, hydrogenation, carbonylation, fractional distillation, and preparative chromatography for complex API manufacturing projects.
  • Building Blocks Catalog product of chemical intermediates and building blocks for organic synthesis, including cyclobutane derivatives, cyclopropyl compounds, tetrahydropyran derivatives, and other specialized reagents for pharmaceutical synthesis customers.
  • GMP Excipients Pharmaceutical-grade excipients product line including Sodium Stearyl Fumarate GMP and Propyl gallate GMP, meeting USP and EP standards for pharmaceutical formulation customers.
  • Generic APIs Portfolio Portfolio of more than 30 generic active pharmaceutical ingredients supplied under cGMP, including APIs for oncology (vinca alkaloids: Vinblastine, Vincristine, Vindesine, Vinorelbine), cardiovascular, central nervous system, gastrointestinal, and veterinary applications, sold directly to generic drug manufacturers.

Quantifiable outcome

  • Successful FDA inspection completed at Montreal facility (November 2025)
  • +2 more outcomes

Companies that use MINAKEM SAS

Customer profile

Segments2 records

Ideal customer profiles2 records

MINAKEM SAS technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

MINAKEM SAS partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Delmar Chemicals Inc. (Acquisition by Minafin Group)coreStrategic or Co-development Partner · 1 July 2023Minafin Group acquired Delmar Chemicals Inc. in Montreal, Canada in July 2023 to expand its Healthcare Chemicals division and establish presence in North America. The acquisition includes a portfolio of generic active pharmaceutical ingredients and enhances R&D and manufacturing capacities, especially in organic synthesis and corticosteroids. This enables Minakem to serve the North American market directly.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

MINAKEM SAS competitors and assessment

Company assessment

Direct peers

  • Hovione: Hovione is a privately held, Portugal-based CDMO specializing in small-molecule APIs and HPAPIs with manufacturing in Europe and the U.S. It is the closest functional comparable to Minakem in terms of HPAPI containment levels, complex chemistry (cryogenic, particle engineering) and CDMO-plus-generics mix.
  • Siegfried Holding: Siegfried is a Swiss-listed CDMO offering API manufacturing plus finished dosage forms with sites in Switzerland, the U.S., Germany, Spain and Malta. Comparable to Minakem in small-molecule API CDMO model and global multi-site footprint, though larger and more integrated into drug product.
  • EuroAPI: EuroAPI is a French API manufacturer spun out of Sanofi, focused on small-molecule APIs and intermediates across steroids, hormones and complex chemistry. It mirrors Minakem's European footprint, steroid franchise and CDMO activity, and is a directly comparable European API specialist competitor.
  • Seqens (PCAS): Seqens is a France-based specialty chemicals and pharmaceutical CDMO producing APIs, intermediates and complex molecules across multiple sites. It is comparable to Minakem as a French-headquartered, multi-site API CDMO serving global pharma with similar chemistry capabilities.
  • Cambrex: Cambrex is a U.S.-headquartered CDMO focused exclusively on small-molecule APIs and intermediates with HPAPI capabilities across North America and Europe. Acquired by Permira/Novo Holdings, it competes head-on with Minakem in custom API development, scale-up and commercial supply.
  • Veranova (formerly Johnson Matthey Health): Veranova is a CDMO spun out of Johnson Matthey in 2023 specializing in HPAPIs, complex APIs and antibody-drug conjugate payloads. It is highly comparable to Minakem given shared HPAPI focus, containment capabilities and oncology customer base.
  • CARBOGEN AMCIS (Dishman): CARBOGEN AMCIS is a Switzerland/India-headquartered CDMO with strong HPAPI capabilities, complex chemistry and a global API manufacturing network. Comparable to Minakem in HPAPI containment, complex synthesis and integrated development-to-commercial services.

Broad incumbents

  • Lonza Small Molecules: Lonza operates the world's largest CDMO franchise spanning small-molecule APIs, biologics and cell & gene therapies. Its small-molecules division competes directly with Minakem in API development and HPAPI manufacturing but offers a far broader integrated services portfolio.
  • Catalent: Catalent (now under Novo Holdings) is a global CDMO offering drug substance (including HPAPI) and drug product services across biologics, softgel and inhalation. It overlaps with Minakem in HPAPI and small-molecule API CDMO but is much larger and more diversified.

Emerging players

  • Aurobindo / Apitoria Pharma: Aurobindo and its CDMO arm Apitoria operate large-scale generic API manufacturing globally, including corticosteroids and complex small molecules. Comparable to Minakem's generic API supply business, though with a much larger commercial-scale footprint and broader finished-dose integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MINAKEM SAS social profiles

Digital presence

MINAKEM SAS compliance and trust

Trust signal

Compliance12 records

MINAKEM SAS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MINAKEM SAS leadership team

Management profile

Number of profiles

Profiles5 records

MINAKEM SAS subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MINAKEM SAS funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MINAKEM SAS M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MINAKEM SAS

What does MINAKEM SAS do?

Minakem is a B2B Contract Development and Manufacturing Organization (CDMO) that develops and manufactures Active Pharmaceutical Ingredients (APIs), including highly potent APIs (HPAPIs), controlled substances, and steroids, for pharmaceutical companies worldwide. It provides custom process development, analytical method development, scale-up, technology transfer, and commercial supply from four cGMP-compliant production facilities in France, Belgium, and Canada. Its portfolio also includes more than 30 generic APIs, GMP excipients, and chemical building blocks for organic synthesis.

Is MINAKEM SAS a public or private company?

MINAKEM SAS is a private company. It is classified as corporate owned and is currently operating.

When was MINAKEM SAS founded?

MINAKEM SAS was founded in 1964. It employs 501 to 1,000 people.

Where is MINAKEM SAS based?

MINAKEM SAS is headquartered in Dunkerque, France, in the Europe region.

How does MINAKEM SAS make money?

Two revenue lines are on record. API Manufacturing Services are the primary driver. The others are generic API Supply.

Who are MINAKEM SAS's main competitors?

Direct peers on record are Hovione, Siegfried Holding, EuroAPI, Seqens (PCAS), Cambrex, Veranova (formerly Johnson Matthey Health) and CARBOGEN AMCIS (Dishman). Broad incumbents are Lonza Small Molecules and Catalent. Aurobindo / Apitoria Pharma is listed as an emerging player.

Does MINAKEM SAS have an API?

No public API is recorded for MINAKEM SAS.

What industry is MINAKEM SAS in?

MINAKEM SAS's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAC, High-Potency API (HPAPI) Development & Manufacturing. Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals